Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Agent Capital

Investor type Micro VC


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 27
Average round size
The average size of a deal this fund participated in
Portfolio companies 18
Rounds per year 4.50
Lead investments 0
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 3
Key employees 3
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Life Science

The company was established in North America in United States. The main department of described VC is located in the Cambridge.

Among the most popular fund investment industries, there are Genetics, Health Care. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Orchard Therapeutics, Skyhawk Therapeutics, Skyhawk Therapeutics. The fund has specific favorite in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund.

The overall number of key employees were 3.

The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year. The real fund results show that this VC is 9 percentage points less often commits exit comparing to other companies. This Agent Capital works on 4 percentage points more the average amount of lead investments comparing to the other organizations. The usual things for fund are deals in the range of 50 - 100 millions dollars. The top amount of exits for fund were in 2018.

The typical case for the fund is to invest in rounds with 9-10 participants. Despite the Agent Capital, startups are often financed by Tim Disney, The Duke of Bedford, F-Prime Capital. The meaningful sponsors for the fund in investment in the same round are Alexandria Venture Investments, Cowen Healthcare Investments, Wellington Partners. In the next rounds fund is usually obtained by Venrock, Tim Disney, The Duke of Bedford.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Agent Capital:
Typical Co-investors
Agent Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Agent Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Celerity Partners California, Los Angeles, United States
Chongqing Cultural Investment Group Beibei, China, Chongqing
CIBC Bank Chicago, Illinois, United States
CICC Qide -
Dick Clark Productions California, Santa Monica, United States
Future Go Beijing, China, Haidian
General Instrument Horsham, Pennsylvania, United States
Hainan Haiyao Co. China, Haikou, Hainan
Halifax Group District of Columbia, United States, Washington
Huaqiang Ziben -
Joincare Pharmaceutical China, Guangdong, Shenzhen
Kainos Belfast, Northern Ireland, United Kingdom
Kingspan Cavan, County Cavan, Ireland
Neyer Holdings Corporation Cincinnati, Ohio, United States
Omaha Capital China China, Hong Kong, Hong Kong Island
Puju Ventures -
Rana Investment Ar Riyad, Riyadh, Saudi Arabia
SOFINDEV Belgium, Flemish Brabant, Vlaams-Brabant
The Stable Fund -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Palvella Therapeutics

Health Care
Life Science
$37M05 Jan 2023 Radnor Township, Pennsylvania, United States

Carisma Therapeutics

Health Care
Life Science
$30M21 Sep 2022 Philadelphia, Pennsylvania, United States

Carbon Biosciences

Product Research
$38M21 Jun 2022 Lexington, Massachusetts, United States

Vittoria Biotherapeutics

Test and Measurement
$10M07 Jun 2022 Philadelphia, Pennsylvania, United States

Affini-T Therapeutics

Health Care
$175M22 Mar 2022 Watertown, Massachusetts, United States

Cyrus Biotechnology

$18M06 Dec 2021 Seattle, Washington, United States

Entrada Therapeutics

Emergency Medicine
Health Care
$116M31 Mar 2021 Boston, Massachusetts, United States

Pyxis Oncology

Health Care
$152M30 Mar 2021 Boston, Massachusetts, United States

Mediar Therapeutics

17 Mar 2021 Cambridge, Massachusetts, United States
Immunitas Therapeutics Closes $58M in Series B Financing

– Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing.
– The round was led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society . Existing investors Alexandria Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund (NVF), and founding investor Longwood Fund also joined the round.
– The company intends to use the funds to advance its lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies.

Entrada Therapeutics Closes $116M Series B Financing

– Entrada Therapeutics from Boston develops intracellular biologics to treat devastating diseases.
– The company closed a $116m Series B financing.
– The round was led by Wellington Management Company and joined by Redmile Group, TCG Crossover, Greenspring Associates, Point72, Qatar Investment Authority (“QIA”), Moore Strategic Ventures, Goldman Sachs, CureDuchenne Ventures and one undisclosed global investment firm.
– Existing investors 5AM Ventures, MPM Capital, Roche Venture Fund, MRL Ventures Fund and Agent Capital also participated in the financing.
– The new investment will be used to advance its pipeline to the clinic.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Agent Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: